Colin Edge
Overview
Explore the profile of Colin Edge including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
119
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Barron B, Edge C, Fenner S, Shrives H, Sollis S, Whiting M, et al.
Org Lett
. 2024 Feb;
26(8):1533-1538.
PMID: 38363757
A highly enantioselective organocatalytic aza-Michael addition of 4-nitro-pyrazole to ethyl ()-2,2-difluoro-5-oxopent-3-enoate has been developed. This reaction enabled a concise, four-step, stereoselective synthesis of highly functionalized 3,3-difluoro-4-pyrazolo-piperidine GSK3901383A, a key intermediate...
2.
Hutchison I, Ridout F, Cheung S, Shah N, Hardee P, Surwald C, et al.
Br J Cancer
. 2021 Dec;
126(5):831.
PMID: 34949789
No abstract available.
3.
Hutchison I, Ridout F, Cheung S, Shah N, Hardee P, Surwald C, et al.
Br J Cancer
. 2019 Oct;
121(10):827-836.
PMID: 31611612
Background: Guidelines remain unclear over whether patients with early stage oral cancer without overt neck disease benefit from upfront elective neck dissection (END), particularly those with the smallest tumours. Methods:...
4.
Ding X, Stasi L, Dai X, Long K, Peng C, Zhao B, et al.
Bioorg Med Chem Lett
. 2018 Dec;
29(2):212-215.
PMID: 30522952
We describe the discovery and optimization of 5-substituted-N-pyridazinylbenzamide derivatives as potent and selective LRRK2 inhibitors. Extensive SAR studies led to the identification of compounds 18 and 23, which demonstrated good...
5.
Cipcigan F, Carrieri A, Pyzer-Knapp E, Krishna R, Hsiao Y, Winn M, et al.
J Chem Phys
. 2018 Jul;
148(24):241744.
PMID: 29960328
Simulation and data analysis have evolved into powerful methods for discovering and understanding molecular modes of action and designing new compounds to exploit these modes. The combination provides a strong...
6.
Ding X, Stasi L, Ho M, Zhao B, Wang H, Long K, et al.
Bioorg Med Chem Lett
. 2018 Mar;
28(9):1615-1620.
PMID: 29588215
Inhibition of LRRK2 kinase activity with small molecules has emerged as a potential novel therapeutic treatment for Parkinson's disease. Herein we disclose the discovery of a 4-ethoxy-7H-pyrrolo[2,3-d]pyrimidin-2-amine series as potent...
7.
Ding X, Dai X, Long K, Peng C, Andreotti D, Bamborough P, et al.
Bioorg Med Chem Lett
. 2017 Aug;
27(17):4034-4038.
PMID: 28774425
Leucine-rich repeat kinase 2 (LRRK2) has been suggested as a potential therapeutic target for Parkinson's disease. Herein we report the discovery of 5-substituent-N-arylbenzamide derivatives as novel LRRK2 inhibitors. Extensive SAR...
8.
Bax B, Chung C, Edge C
Acta Crystallogr D Struct Biol
. 2017 Feb;
73(Pt 2):131-140.
PMID: 28177309
There are more H atoms than any other type of atom in an X-ray crystal structure of a protein-ligand complex, but as H atoms only have one electron they diffract...
9.
Leveridge M, Collier L, Edge C, Hardwicke P, Leavens B, Ratcliffe S, et al.
J Biomol Screen
. 2015 Sep;
21(2):145-55.
PMID: 26403521
LRRK2 is a large multidomain protein containing two functional enzymatic domains: a GTPase domain and a protein kinase domain. Dominant coding mutations in the LRRK2 protein are associated with Parkinson's...
10.
Li D, Howe N, Dukkipati A, Shah S, Bax B, Edge C, et al.
Cryst Growth Des
. 2014 May;
14(4):2034-2047.
PMID: 24803849
The lipidic mesophase or in meso method for crystallizing membrane proteins has several high profile targets to its credit and is growing in popularity. Despite its success, the method is...